Search

Your search keyword '"Eichenauer, Dennis A."' showing total 158 results

Search Constraints

Start Over You searched for: Author "Eichenauer, Dennis A." Remove constraint Author: "Eichenauer, Dennis A." Database Unpaywall Remove constraint Database: Unpaywall
158 results on '"Eichenauer, Dennis A."'

Search Results

1. Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange

2. Involved-site radiotherapy is equally effective and less toxic than Involved-field radiotherapy in patients receiving combined modality treatment for early-stage unfavorable Hodgkin lymphoma - an analysis of the randomized phase III HD17 trial of the German Hodgkin Study Group

4. Handoffs in the intensive care unit

5. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

7. Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis

11. Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

13. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

14. Management of Immune Thrombotic Thrombocytopenic Purpura Without Therapeutic Plasma Exchange

16. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

17. Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis

18. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)

19. P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma

20. T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

21. Teamspezifische Auswirkungen der Corona-Pandemie auf Mitarbeiter:innen der Internistischen Intensivmedizin eines Krankenhauses der Maximalversorgung

22. Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte‐predominant Hodgkin lymphoma

25. Alternate‐day dosing of caplacizumab for immune‐mediated thrombotic thrombocytopenic purpura

26. Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group

28. Veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe respiratory failure in adult cancer patients: a retrospective multicenter analysis

29. Aspergillus tracheobronchitis in COVID-19 ARDS patients – a cohort study

30. Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt Lymphoma and High‐Grade B‐Cell Lymphoma

31. Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma

34. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)

35. Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura

36. PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

38. Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

40. Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes—results of a retrospective analysis from a German university hospital

41. First use of the anti‐VWF nanobody caplacizumab to treat iTTP in pregnancy

42. Clinical Course and Outcome of Patients with SARS-CoV-2 Alpha Variant Infection Compared to Patients with SARS-CoV-2 Wild-Type Infection Admitted to the ICU

45. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

46. Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group

48. Update 2021: COVID-19 aus Sicht der Intensivmedizin

49. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

Catalog

Books, media, physical & digital resources